Glycosidase inhibitors
Compounds of formula (I) wherein X 1 , X 2 , W, R 1 to R 5 , L and m have the meaning according to the claims, are glucosidase inhibitors, and can be employed, inter alia, for the treatment of Alzheimer's disease.
1. A compound of formula
wherein:
R 2 denotes COY, COAlk, CONY 2 or COOY;
R 5 denotes (CY 2 ) q Ar, Cyc or A;
Y denotes H or A;
A denotes unbranched or branched alkyl having 1-10 C atoms,
in which 1-7 H atoms can be replaced independently from one another by Hal;
Alk denotes unbranched or branched alkenyl having 2-6 C atoms;
in which 1-3 H atoms can be replaced independently from one another by Hal;
Cyc denotes cycloalkyl having 3-7 C atoms; in which 1-4 H atoms can be replaced independently from one another by Hal;
Ar denotes an unsaturated or aromatic mono- or bicyclic carbocycle having 4-12 C atoms, which can be substituted by at least one substituent selected from the group of Hal, A, OY, COOY and CN;
Hal denotes F, Cl, Br or I;
q denotes 0, 1 or 2; and
and/or a physiologically acceptable salt thereof.
2. The compound according to claim 1 selected from the group of:
and/or a physiologically acceptable salt thereof.
3. A pharmaceutical composition comprising as active ingredient an effective amount of a compound according to claim 1 , wherein the active ingredient is provided together with pharmaceutically tolerable adjuvants and/or excipients in the pharmaceutical composition, optionally in combination with one or more further active ingredients.